Class 01 · Incretins · GIP / GLP-1 dual receptor agonist · "twincretin"

Tirzepatidethe twincretin · FDA-approved (T2DM · obesity · OSA)

Eli Lilly's first-in-class dual incretin — the first medicine to activate both the GIP and GLP-1 hormone receptors at once. Sold as Mounjaro for type 2 diabetes and Zepbound for obesity and sleep apnea. In the head-to-head obesity trial against semaglutide (Wegovy), patients lost an average of 20.2% of body weight at 72 weeks — about 50 pounds. FDA approved for T2DM (May 2022), obesity (Nov 2023), and moderate-to-severe OSA in adults with obesity (Dec 2024).

LY3298176 — once-weekly SC dual agonist of GIP and GLP-1 receptors. Single 39-amino-acid peptide with C20 fatty-diacid linker at Lys20 for albumin binding (~5-day half-life). SURMOUNT-1 (NEJM 2022): −20.9% weight at 15 mg over 72 weeks · SURPASS-2 vs semaglutide: −2.46% HbA1c (15 mg) · SURPASS-CVOT (NEJM 2025): non-inferior MACE-3 vs dulaglutide with 16% lower all-cause mortality. Three approved indications; six SURPASS, five SURMOUNT, and a fully read-out CVOT define the program.

Single 39-AA peptide engineered on a GIP backbone with non-canonical residues (Aib2, Aib13) and a γ-Glu/2×OEG-C20 diacid moiety acylated at Lys20 enabling reversible albumin binding. Binds GIPR with Ki ≈ 0.135 nM (near-native GIP affinity) and GLP-1R with Ki ≈ 4.23 nM (~5× weaker than native GLP-1). Functionally an "imbalanced and biased" agonist — full cAMP activation at GIPR with skewed β-arrestin recruitment at GLP-1R compared with semaglutide. Cryo-EM-resolved at both Class B1 GPCRs. CAS 2023788-19-2; molecular formula C225H348N48O68; MW 4813.5 g/mol.

−20.9% Weight loss · SURMOUNT-1 · 15mg · 72 wk

−2.58% HbA1c · SURPASS top dose · ~40 wk

~5d Half-life · weekly SC

39 AA Peptide length · MW 4813.5

Status

FDA-approved · 3 indications

Open dose calculator →

Frequency

Once weekly SC

Sponsor

Eli Lilly

Next inflection

SURMOUNT-MMO read-out (2026+)

Molecule identity

C₂₂₅H₃₄₈N₄₈O₆₈

Acylated 39-amino-acid GIP-backbone peptide · LY3298176 · Mounjaro · Zepbound · γ-Glu/2×OEG-C20 at Lys20 · synthetic SPPS · 4813.5 Da

ClassDual GIP/GLP-1 receptor agonist (twincretin)

SequenceY-Aib-EGTFTSDYSI-Aib-LDKIAQKAFVQWLIAGGPSSGAPPPS-NH₂ (39 aa · Aib2 · Aib13 · C20-diacid @ Lys20)

Backbone originGIP-like; engineered for GLP-1R affinity

Molecular weight4813.5 Da · C₂₂₅H₃₄₈N₄₈O₆₈ (free base)

Primary targetsGIPR · GLP-1R

Plasma half-life~5 days (~120 h) · weekly SC

RouteSubcutaneous · pre-filled single-dose pen

Tmax8–72 h (population PK)

Steady state~4 weeks of weekly dosing

Storage2–8 °C refrigerated · 21 d room temp allowance

Dose range2.5 mg (start) → 15 mg (max) weekly

GIPR affinity (Ki)~0.135 nM (≈native GIP)

GLP-1R affinity (Ki)~4.23 nM (~5× weaker than native GLP-1)

Signaling biasImbalanced/biased at GLP-1R · full cAMP at GIPR

Albumin binding>99% protein-bound · C20 diacid + linker · DPP-4 resistant

Bioavailability (SC)~80% absolute (ADME estimate)

MetabolismProteolysis (DPP-4 cleavage, Aib-protected) + fatty-acid β-oxidation · renal/fecal metabolite excretion

Renal / hepatic dosingNo adjustment for any degree of impairment

PubChem CID168009818 · DrugBank DB15171 · KEGG D11360

First approvalMay 13, 2022 (Mounjaro · T2DM)

EMA statusAuthorized T2DM Sep 15, 2022 · weight mgmt added Apr 2024 (KwikPen)

WADA 2026Not prohibited · markers added to Monitoring Program (in- & out-of-competition)

CompoundingShortage resolved Oct 2024 · 503A ended Feb 18, 2025 · 503B Mar 19, 2025 · documented allergy only

01 · At a glance

Key facts & headline data.

The most-cited numbers across the SURPASS, SURMOUNT, SUMMIT, SYNERGY-NASH, and SURPASS-CVOT programs — the metrics that defined tirzepatide as the first dual-incretin medicine and the current best-in-class agent for combined weight and glycemic management.

⚖️

Weight loss · obesity without diabetes

−20.9%

SURMOUNT-1 (NEJM 2022, n=2,539): tirzepatide 15 mg weekly produced −20.9% mean change in body weight at 72 weeks (95% CI −21.8 to −19.9), vs −3.1% with placebo. 5 mg: −15.0%; 10 mg: −19.5%. Three-year extension maintained −19.7% at 176 weeks. The largest weight-loss outcome ever seen in an obesity RCT prior to retatrutide.

📉

HbA1c · top dose across SURPASS

−2.58%

Across SURPASS 1–5, tirzepatide 5–15 mg weekly reduced HbA1c by 1.24–2.58% from baselines of ~8.0–8.5%, with 23–62% of participants achieving HbA1c <5.7% (normoglycemia) without increased severe hypoglycemia. Greater glycemic effect than any prior monotherapy GLP-1 RA at standard doses.

🆚

vs Semaglutide · obesity (SURMOUNT-5)

−20.2 vs −13.7

SURMOUNT-5 (NEJM 2025, head-to-head, n=751): tirzepatide 10/15 mg vs semaglutide 1.7/2.4 mg over 72 weeks — LSM weight change −20.2% vs −13.7% (P<0.001); waist circumference −18.4 vs −13.0 cm; significantly higher proportions hit ≥10/15/20/25% loss thresholds. The first definitive head-to-head obesity comparison.

❤️

SURPASS-CVOT · MACE-3 vs dulaglutide

−8% / −16% ACM

SURPASS-CVOT (NEJM 2025, n>13,000, median 4 yr follow-up): tirzepatide non-inferior to dulaglutide on MACE-3 with an 8% lower event rate, 16% lower all-cause mortality, and improved A1c, weight, BP, and renal function. The first CVOT for a dual incretin.

😴

OSA · AHI reduction (SURMOUNT-OSA)

−27.4 ev/h

SURMOUNT-OSA (NEJM 2024, n=469): tirzepatide reduced AHI by 27.4 events/hour (Study 1, non-PAP) and 29.3 events/hour (Study 2, on-PAP) vs 4.8 and 5.5 with placebo at 52 weeks. ~50% of patients had AHI reductions large enough to no longer meet OSA criteria. FDA approval Dec 20, 2024 — first medicine indicated for OSA.

🫀

HFpEF · CV death/worsening HF

−38%

SUMMIT (NEJM 2024, n=731): in obesity-related HFpEF (LVEF ≥50%, BMI ≥30), tirzepatide reduced the composite of CV death or worsening HF events by 38% over 104 weeks; KCCQ-CSS improved by +6.9 points and 6MWD by ~+18 m at 52 weeks. Re-defines pharmacologic HFpEF management.

🩺

MASH resolution · SYNERGY-NASH

73.3%

SYNERGY-NASH (NEJM 2024, n=190, phase 2): biopsy-proven MASH resolution without worsening fibrosis at 52 weeks — 51.8% (5 mg), 62.8% (10 mg), 73.3% (15 mg) vs 13.2% placebo. Fibrosis improvement (≥1 stage): up to 59.1% vs 32.8% placebo. Phase 3 ongoing.

🛡️

Prediabetes → T2DM (3-yr extension)

HR 0.07

SURMOUNT-1 three-year extension (NEJM 2025, n=1,032 with obesity + prediabetes): progression to T2DM 1.3% with tirzepatide vs 13.3% with placebo (HR 0.07, 95% CI 0.02–0.24) at 176 weeks. Off-treatment 17-week follow-up: HR 0.12 — durable risk reduction.

02 · Mechanism of action

How a twincretin works.

Tirzepatide imitates two gut hormones — GIP and GLP-1 — that your body normally releases after a meal. These hormones tell the pancreas to release insulin, tell the brain you're full, and slow how fast food leaves the stomach. By activating both at once with a single molecule, tirzepatide produces more weight loss and bigger drops in blood sugar than activating just GLP-1 (like Wegovy or Ozempic).

Tirzepatide is a co-agonist of two Class B1 GPCRs — GIPR and GLP-1R — that together govern the incretin effect (the post-meal amplification of glucose-stimulated insulin secretion). GIPR binding affinity approximates native GIP (Ki ≈ 0.135 nM); GLP-1R binding is ~5-fold weaker than native GLP-1 (Ki ≈ 4.23 nM), but receptor activation is functionally balanced with a distinctive "biased" cAMP-skewed signaling signature. The composite phenotype: glucose-dependent insulin secretion, postprandial glucagon suppression, delayed gastric emptying, central appetite reduction, and a previously-undescribed adipose-tissue insulin-sensitizing effect attributable to GIPR — which dual agonism uniquely delivers.

Tirzepatide's pharmacology is defined by three interlocking design choices: (1) a GIP backbone modified at positions 2 and 13 with α-aminoisobutyric acid (Aib) to prevent DPP-4 cleavage; (2) acylation at Lys20 with a γ-Glu/2×OEG-linked C20 fatty diacid for reversible albumin binding (~5-day human half-life); (3) a sequence rebalanced for sub-nanomolar GIPR and low-nanomolar GLP-1R activity. In recombinant systems, tirzepatide produces robust cAMP at GIPR and "imbalanced" GLP-1R signaling, with reduced β-arrestin recruitment relative to native GLP-1 and semaglutide — a profile termed "imbalanced and biased" dual agonism. In primary human islets, GIPR engagement is required for full insulin- and glucagon-secretory effects; GLP-1R activation alone cannot reproduce the response. Beyond the pancreas, GIPR is expressed on adipocytes, where dual signaling appears to drive a unique improvement in adipose insulin sensitivity and lipid handling not seen with selective GLP-1 RAs.

🎯

GIPR · the rebalanced partner

Tirzepatide binds GIPR with Ki ≈ 0.135 nM — comparable to native GIP — and produces full cAMP activation downstream. In primary human islet preparations, GIPR engagement is required for the full insulin- and glucagon-secretory response; GLP-1R activation alone does not reproduce the islet effect. This is the receptor arm that distinguishes tirzepatide from semaglutide and dulaglutide.

Clinical significance: GIPR agonism adds to GLP-1R by recruiting GIPR-expressing tissues (adipose, bone, certain CNS nuclei) that selective GLP-1 RAs do not directly engage. Adipocyte GIPR signaling improves insulin sensitivity and lipid handling; GIPR engagement in the area postrema may also modulate the nausea-vs-satiety balance, potentially explaining tirzepatide's favorable tolerability per unit weight loss vs equipotent selective GLP-1 RAs.

Molecular detail: GIPR is a Class B1 GPCR primarily coupled to Gαs → adenylyl cyclase → cAMP / PKA. Tirzepatide produces full cAMP at GIPR with EC50 in the picomolar–low-nanomolar range across multiple cell-based assays. Receptor internalization assays show EC50 ≈ 18.2 nM at GIPR vs 18.1 nM at GLP-1R — functionally balanced internalization despite asymmetric binding affinities. The "rebalancing" toward GIPR is intentional: native GIP is weakly insulinotropic in T2DM (a long-standing pharmacologic puzzle) but partial GIPR agonism appears to restore some of that lost activity in the pathologic state. Whether GIPR signaling is best understood as "agonist" or "biased agonist/functional antagonist" in vivo remains debated — but the clinical phenotype is settled.

🧬

GLP-1R · the classical incretin axis

Tirzepatide is a full agonist at GLP-1R, though with ~5-fold lower binding affinity than native GLP-1 (Ki ≈ 4.23 nM) and a distinctive signaling-bias profile vs semaglutide. The GLP-1R arm delivers the classical incretin effects: glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite reduction through arcuate POMC neurons and brainstem satiety centers.

Clinical significance: The GLP-1R arm accounts for most of the appetite-suppression and gastric-emptying phenotype, and explains why GI tolerability and discontinuation rates with tirzepatide cluster with selective GLP-1 RAs rather than with the (essentially absent) GI burden of pure GIP agonists. Glucagon suppression is glucose-dependent — hypoglycemia in monotherapy is rare, but markedly elevated when combined with insulin or sulfonylureas.

Molecular detail: At GLP-1R, tirzepatide produces robust cAMP signaling but reduced β-arrestin recruitment compared with native GLP-1 and semaglutide — the "imbalanced and biased" signature. β-arrestin recruitment drives GPCR internalization and desensitization; biased ligands that avoid arrestin recruitment may produce more sustained downstream signaling. This bias is one proposed explanation for tirzepatide's greater per-dose efficacy vs equipotent selective GLP-1 RAs. Across SURPASS 1–5, 23–62% of T2DM patients reach HbA1c <5.7% on tirzepatide monotherapy or with metformin — a normoglycemia rate previously unattainable with GLP-1 RAs.

📉

Adipose tissue · the GIPR-unique lever

Adipocytes express GIPR (not GLP-1R) and respond to GIPR agonism with improved insulin sensitivity, accelerated postprandial triglyceride clearance, and selective reductions in visceral and hepatic fat depots. This is the tissue compartment where dual agonism most clearly outperforms selective GLP-1R agonism, and is mechanistically responsible for the disproportionate visceral fat and liver fat reductions seen with tirzepatide vs semaglutide.

Clinical significance: SURMOUNT-5 (vs semaglutide) showed not only superior absolute weight loss but markedly greater waist-circumference reduction (−18.4 cm vs −13.0 cm) — pointing to preferential visceral adipose depot reduction. In SYNERGY-NASH, MRI-PDFF liver fat fell by >80% at higher doses and MASH resolution reached 73.3% (15 mg) vs 13.2% placebo. Body composition substudies show that ~75% of mass lost is fat (with the remaining ~25% lean) — a proportionally fat-favoring loss pattern, although the absolute amount of lean tissue lost is non-trivial and is the basis for the lean-mass-preservation literature emerging around resistance training plus incretin therapy.

Molecular detail: Adipocyte GIPR activation engages Gαs/cAMP/PKA-driven hormone-sensitive lipase regulation and clears postprandial triglycerides via increased adipose lipoprotein lipase activity. In rodent and human adipose explants, GIPR agonism (in the context of dual signaling) increases insulin-stimulated glucose uptake and lipid storage selectively in subcutaneous depots while reducing inflammation in visceral depots. Whether the favorable body-composition signal is GIPR-specific or a consequence of overall greater weight loss is partially settled — pair-feeding studies in rodents and DEXA substudies in humans support a true tissue-selective effect.

🧠

CNS · appetite, satiety, & reward

Both GLP-1R and GIPR are expressed on hypothalamic and brainstem nuclei involved in energy intake regulation. GLP-1R signaling in the arcuate (POMC neurons), paraventricular, and nucleus tractus solitarius produces robust satiety and meal-size reduction. GIPR signaling in the area postrema appears to modulate the nausea-vs-satiety balance — a possible explanation for tirzepatide's relatively favorable GI tolerability per unit of weight loss compared with high-dose selective GLP-1 RAs.

Clinical significance: Patients on tirzepatide typically describe reduced food preoccupation, smaller meal sizes, earlier satiation, and reduced reward-driven eating ("food noise"). Delayed gastric emptying contributes to mechanical satiety in the early titration period; the central effects dominate at steady state. Re-introduction of food after dose holds or discontinuation produces rapid return of appetite — the basis for SURMOUNT-4's demonstration of weight regain on withdrawal.

Molecular detail: Imaging studies (fMRI of food-cue reactivity) show that incretin therapy reduces reward-area activation to high-palatability food cues. Tirzepatide's signaling bias at GLP-1R — reduced β-arrestin recruitment — may underlie a more sustained CNS pharmacodynamic effect compared with selective GLP-1 RAs. The relative role of GIPR signaling in the area postrema in modulating nausea is the most active area of mechanistic investigation; pharmacologic-genetic dissection in mice supports GIPR engagement as causal to the favorable tolerability profile.

❤️

Cardiovascular · MACE, BP, lipids, HFpEF

SURPASS-CVOT (NEJM 2025) established that tirzepatide is non-inferior to dulaglutide on MACE-3 with a numerically 8% lower event rate, a significantly 16% lower all-cause mortality, and superior secondary endpoints on BP, weight, A1c, and renal function. SUMMIT (NEJM 2024) separately established a 38% reduction in CV death or worsening HF events in obesity-related HFpEF.

Clinical significance: The CV story for tirzepatide is now substantially settled. Tirzepatide preserves the cardioprotective signal of dulaglutide while delivering meaningfully greater metabolic and renal benefit; a broader 4-point MACE (adding coronary revascularization) was significantly lower with tirzepatide (16.5% vs 18.5%). In HFpEF with obesity (SUMMIT), the combined CV-death/worsening-HF endpoint dropped by 38% over 104 weeks with marked improvements in KCCQ-CSS, 6MWD, and weight. Tirzepatide is the first medicine with prospective RCT evidence for HFpEF — separately from any direct natriuretic action — through weight-loss-mediated hemodynamic improvement.

Molecular detail: The CV signal is multifactorial: BP reduction (typically −5 to −8 mmHg systolic), lipid improvements (notably triglyceride reduction), weight loss (with proportional reduction in cardiac filling pressures and pulmonary congestion in HFpEF), improved insulin sensitivity, and possibly direct cardiac effects via myocardial GLP-1R expression (mostly atrial; ventricular expression remains contested). In SURPASS-CVOT, the CV-death/HF-hospitalization composite occurred in 7.8% vs 8.5% — directionally favoring tirzepatide. Subsequent subgroup analyses in baseline HF showed greater relative benefit in higher-risk patients.

🫘

Renal · eGFR, UACR, & CKD progression

Tirzepatide reduces albuminuria and slows eGFR decline in patients with T2DM and CKD, with consistent signal across SURPASS-4 post-hoc and SURPASS-CVOT secondary endpoints. The mechanism overlaps with that of selective GLP-1 RAs (hemodynamic, anti-inflammatory, weight-mediated) but the magnitude appears at least comparable, and possibly greater, in patients with concurrent obesity.

Clinical significance: In SURPASS-CVOT, kidney function (eGFR by CKD-EPI-Cr-CysC 2021) was preserved more effectively with tirzepatide than dulaglutide over 36 months, particularly in patients with KDIGO 2025 high- or very-high-risk CKD. Dedicated CKD-outcome RCTs (analogous to FLOW for semaglutide) are pending. In the absence of dedicated renal-outcome trials, tirzepatide is reasonable to use in T2DM with CKD; SGLT2i remains first-line for CKD-specific renal protection but tirzepatide adds incremental benefit and is mechanistically complementary.

Molecular detail: Direct renal GLP-1R expression is limited (proximal tubule, vascular endothelium); most of the renal benefit is hemodynamic and metabolic — reduced glomerular hyperfiltration through afferent arteriolar vasoconstriction (analogous to but distinct from SGLT2i tubuloglomerular feedback), reduced albuminuria via improved endothelial function, and reduced renal lipotoxicity through weight loss. The CKD-EPI-Cr-CysC 2021 equation (rather than the older 2009 creatinine-only equation) is now standard for tirzepatide-treated patients because of weight-mediated muscle mass changes that affect creatinine generation.

L3 · Downstream pathway

Tirzepatide → GIPR + GLP-1R → Tissue effects → Phenotype → Outcomes

💉

SC dose
(weekly)

→

🩸

Albumin-bound
circulation

→

🎯

GIPR +
GLP-1R

→

🧪

Multi-tissue
signaling

→

⚖️

Glycemia +
energy balance

→

📉

Weight loss
+ metabolic

→

🏆

Hard
outcomes

03 · Dosing protocols & models

Protocol-specific dosing architecture.

Unlike most peptides on this Atlas, tirzepatide carries FDA-approved prescribing information (Mounjaro, Zepbound) with a validated, label-defined dose ladder — so the architecture below is evidence-grounded (Grade A) rather than speculative. It is administered as a once-weekly subcutaneous injection from a single-dose prefilled pen. The titration ladder is shared across all three approved indications (T2DM, obesity, OSA), while maintenance targets and adjunct-medication adjustments differ. Each protocol is built to the same skeleton: starting dose, escalation cadence, dose ladder, maintenance target, cycle/continuation structure, dose math, monitoring overlay, and explicit evidence grade — anchored by a global dose-band table, weight-band reference, engine-ready titration logic, and a biomarker monitoring scaffold. Off-label dose extrapolation beyond the 15 mg label ceiling remains Grade D.

Important · regulatory status Tirzepatide is FDA-approved as Mounjaro for type 2 diabetes (May 13, 2022), Zepbound for chronic weight management in obesity/overweight with comorbidity (November 8, 2023), and Zepbound for moderate-to-severe OSA in adults with obesity (December 20, 2024). The protocols below are derived from FDA prescribing information and pivotal trial schedules. Compounded tirzepatide is no longer eligible under USP 503A bulks-list enforcement following resolution of the FDA shortage list; FDA has issued multiple safety warnings about compounded products. Approved Lilly product should be used wherever possible.

2026 Label evolution & pipeline SURPASS-CVOT topline (July 2025) and full publication (NEJM 393:2409-2420, Dec 2025) support potential label update to include a cardiovascular risk-reduction claim in T2DM. SURMOUNT-MMO (cardiovascular outcomes in obesity without diabetes) continues with results expected 2026+. SYNERGY-NASH-2 (phase 3 MASH) and dedicated CKD-outcome trials are active. Oral tirzepatide and once-monthly long-acting formulations are in earlier development.

Pharmacokinetics · human data (SC route)

Why once-weekly dosing works.

Unlike research peptides dosed as a "pulse signal" against an unmeasured half-life, tirzepatide has a fully characterized population PK model (19 pooled studies, two-compartment, first-order) supporting steady-state weekly dosing. The ~5-day half-life is engineered through reversible albumin binding via the C20 fatty-diacid acylation at Lys20.

Parameter	Value	Note
Route	Subcutaneous only	Abdomen, thigh, or upper arm; rotate sites. No approved oral/IM/intranasal form.
Half-life (t½)	~5 days (~120 h)	Population PK from 19 pooled studies; enables once-weekly dosing.
Tmax	~8–72 h post-dose	Slow absorption from albumin-binding acylation.
Bioavailability (SC)	~80% absolute	Estimated from ADME studies.
Protein binding	>99% (albumin)	Rationale for the extended half-life.
Metabolism	Proteolysis + β-oxidation	DPP-4 cleavage partially blocked by Aib substitution; fatty-acid chain β-oxidized.
Excretion	Renal / fecal (metabolites)	No intact-peptide accumulation.
Steady state	~4 weeks weekly dosing	~4 half-lives; the basis for the 4-week titration step.
Renal / hepatic impairment	No dose adjustment	PK unaffected to a clinically meaningful degree across impairment categories.

Starting dose

2.5 mg once weekly for 4 weeks. This is a starter dose for tolerability — it is NOT a therapeutic dose. Patients should not expect meaningful glycemic or weight effects at 2.5 mg.

Escalation cadence

Step every 4 weeks by 2.5 mg increments if tolerated. Slower escalation (8-week steps) is acceptable for tolerability and does not appear to reduce ultimate efficacy.

Dose ladder

2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg weekly. Six pen strengths available. Stopping at 5, 10, or 15 mg as maintenance is common; 7.5 and 12.5 mg are most often transition doses, though either can serve as maintenance if tolerated and efficacious.

Maximum dose

15 mg once weekly. Doses above 15 mg are not labeled; trial data on doses up to 20 mg are limited and not commercially marketed.

Injection sites

Abdomen (preferred), thigh, or upper arm. Same day each week. Rotate sites weekly to prevent lipohypertrophy. Single-use prefilled pen — each pen is one dose.

Missed dose

If missed dose is within 4 days (96 hours) of scheduled day: administer as soon as possible, then resume regular weekly schedule. If more than 4 days have elapsed: skip the missed dose entirely and resume on the next scheduled day. Do not double-dose. The ~5-day half-life buffers brief gaps but does not justify catch-up dosing.

Storage

Refrigerate at 2–8 °C (36–46 °F) in original carton until use. May be stored at room temperature up to 30 °C (86 °F) for up to 21 days. Do not freeze. Inject within 1 hour of removal from refrigeration for tolerability; warming reduces injection-site discomfort.

PK rationale for 4-week steps

Tirzepatide elimination half-life ≈ 5 days (120 h); steady-state plasma concentrations are reached after ~4 half-lives (≈ 4 weeks of weekly dosing). The 4-week step calibration allows each dose level to reach steady state before tolerability assessment and next escalation.

⚠ Tolerability checkpoint GI adverse events (nausea, vomiting, diarrhea, constipation) peak in the 1–2 weeks following each escalation step. If GI symptoms are severe enough to impair hydration, function, or adherence, hold the current dose for an additional 4 weeks before retrying escalation, or step back to the previously tolerated dose. There is no efficacy penalty for slower titration.

Indication eligibility

Adults with BMI ≥ 30, or BMI ≥ 27 with ≥1 weight-related comorbidity (hypertension, dyslipidemia, T2DM, OSA, established CVD). Used in combination with reduced-calorie diet and increased physical activity.

Standard titration

2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg with 4-week step intervals. SURMOUNT-1 used a 20-week titration period to reach final maintenance dose.

Maintenance targets

Three labeled maintenance doses: 5 mg (−15% mean weight loss at 72 wk), 10 mg (−19.5%), or 15 mg (−20.9%). Higher dose = greater loss with proportionally greater GI burden. Many clinicians titrate to the lowest dose that achieves the desired effect.

Expected timeline

Weight loss curves continue to decline through ~60–72 weeks before plateau. Three-year extension data show maintained −19.7% at 176 weeks on 15 mg maintenance — demonstrating durability without escape on continued therapy.

Response thresholds

If <5% weight loss at 12 weeks of full target dose, reassess: confirm adherence, evaluate for confounding factors, consider dose increase, or consider discontinuation. SURMOUNT-1 efficacy estimand: 91% achieved ≥5% loss (15 mg); 56–63% achieved ≥20%; 32–36% achieved ≥25%.

Adjunct strategy

Pivotal trials embedded a low-deficit nutrition plan and 150 min/week of moderate physical activity. Resistance training 2–3×/week is widely recommended to attenuate lean-mass loss; protein intake 1.2–1.6 g/kg/day. Behavioral support (group or individual) improves adherence to lifestyle adjuncts.

Body composition

DEXA substudies indicate ~75% of mass lost is fat with ~25% lean mass. Visceral and hepatic adipose depots are preferentially reduced (waist circumference −18.4 cm in SURMOUNT-5 at 15 mg over 72 weeks). The lean-mass loss is non-trivial; geriatric and frailty considerations support concurrent resistance training and adequate protein intake, particularly in patients >65 yr or with baseline low muscle mass.

⚠ Withdrawal causes regain SURMOUNT-4 demonstrated that discontinuation of tirzepatide after open-label weight loss produced substantial weight regain over the placebo-randomized follow-up, while continuation maintained and augmented loss. Tirzepatide is appropriately framed as chronic therapy — patient counseling should set expectations for indefinite maintenance or planned, monitored taper.

Initiation

2.5 mg weekly × 4 weeks. Maintenance target individualized by A1c, tolerability, and weight goals — many patients require only 5–10 mg for glycemic control. Higher maintenance (15 mg) often used when weight reduction is a primary co-target.

Expected A1c effect

SURPASS program: 5 mg −1.87% to −2.11%; 10 mg −1.89% to −2.40%; 15 mg −2.07% to −2.58%, depending on baseline and background therapy. Mean baseline A1c 7.9–8.5%.

Background metformin

Continue. Mechanism is complementary (different upstream node). SURPASS-2 demonstrated tirzepatide on a metformin background was superior to semaglutide 1 mg on the same background for both A1c and weight.

Background SGLT2i

Continue. CV/renal benefits stack. Hypoglycemia risk is not meaningfully elevated by SGLT2i alone.

Background insulin

Reduce basal insulin dose by 20% at tirzepatide initiation and titrate further based on glucose response. SURPASS-5 protocol used a similar approach with insulin glargine. Patient self-monitoring or CGM during titration is essential. Prandial insulin can usually be reduced markedly as gastric emptying delays and meal-stimulated insulin secretion improves.

Background sulfonylurea

Reduce SU dose by 50% or discontinue at tirzepatide initiation. SU + tirzepatide carries the highest hypoglycemia risk of any common combination; most clinicians simply discontinue the SU.

DPP-4 inhibitor

Discontinue DPP-4 inhibitor at tirzepatide initiation. The mechanisms overlap (DPP-4i preserves endogenous GLP-1/GIP); the combination provides no additional benefit and adds cost.

Normoglycemia probability

A patient-level analysis across SURPASS-1 to -5 found that 23–62% of tirzepatide-treated participants achieved HbA1c <5.7% (normoglycemia) without increased hypoglycemia. Probability scales with dose, lower baseline A1c, shorter T2DM duration, and lack of background insulin. This is the highest normoglycemia rate documented in any T2DM pharmacotherapy program.

⚠ Hypoglycemia risk on combinations Tirzepatide monotherapy does not cause clinically significant hypoglycemia (insulin secretion is glucose-dependent). Combination with insulin or sulfonylureas markedly elevates hypoglycemia risk and requires proactive dose reduction of the secretagogue/insulin and structured glucose monitoring during titration.

Indication eligibility

Adults with moderate-to-severe OSA (AHI ≥ 15 events/hour) and obesity (BMI ≥ 30). With or without concurrent positive airway pressure (PAP) therapy. Adjunct to reduced-calorie diet and increased physical activity. Not a CPAP/PAP replacement in isolation — discussion with the sleep specialist is required.

Titration

Standard label ladder: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg at 4-week intervals. SURMOUNT-OSA trials used 10 mg or 15 mg maintenance (whichever maximum tolerated dose was reached).

AHI reductions (52-week)

Study 1 (non-PAP, n=234): mean AHI reduction 27.4 events/hour with tirzepatide vs 4.8 with placebo. Study 2 (on-PAP, n=235): mean AHI reduction 29.3 events/hour with tirzepatide vs 5.5 with placebo. Approximately half of treated patients achieved AHI reductions large enough to no longer meet OSA diagnostic criteria.

Concurrent PAP

Tirzepatide can be combined with CPAP/BiPAP. In Study 2, patients continued PAP throughout the 52-week trial; tirzepatide produced additional AHI reduction beyond PAP alone. As patients lose weight, sleep specialist re-titration of PAP pressures may be indicated.

Discontinuation of PAP

Do not discontinue PAP without sleep specialist guidance and repeat polysomnography. A meaningful AHI reduction does not always equate to clinical resolution — daytime sleepiness, hypoxemic burden, and arrhythmia risk must be reassessed separately.

Adjunctive outcomes

Tirzepatide treatment produced weight loss ~18–20% over 52 weeks in the SURMOUNT-OSA population; significant reductions in hs-CRP and BP were also observed, contributing to overall cardiometabolic risk reduction in this high-risk cohort.

Mechanism in OSA

OSA in obesity has a strong mechanical component: parapharyngeal adipose deposition narrows the upper airway during sleep. Tirzepatide's preferential reduction in visceral and ectopic adipose depots, including airway-associated fat, plausibly underlies the larger-than-expected AHI improvement. Independent contributions from improved sleep architecture (less obstructive arousals, less hypoxemic burden) and reductions in ventilatory drive overshoot have been proposed but are not fully resolved.

Rationale

A subset of patients experience marked GI intolerance with standard 4-week step intervals. Slower titration (8-week steps) is well tolerated and does not appear to reduce ultimate efficacy at the same maintenance dose. Appropriate for elderly patients, patients with low BMI starting point, patients with prior incretin intolerance, or patients valuing tolerability over speed-to-effect.

Cadence

Step every 8 weeks rather than 4. Reaching 15 mg requires ~40 weeks rather than ~20.

Dose ladder

Same as label: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg. Many patients on this protocol find adequate effect at 5–10 mg and elect not to push to 15 mg.

Tolerability strategies

Pre-meal hydration, smaller more frequent meals during titration weeks, lower-fat meals, anti-emetic on hand (ondansetron 4–8 mg PRN). Antihistamine (H1 + H2) may help if histamine-mediated symptoms predominate. Avoid alcohol during initial titration.

Step-back option

If intolerable symptoms at a step, return to previously tolerated dose for 8 weeks before retry. There is no efficacy penalty; cumulative time-at-target dose is what determines outcomes.

Geriatric considerations

In adults >75 years, dehydration risk from GI symptoms is non-trivial and can precipitate acute kidney injury. Conservative titration plus weekly weight/orthostatic checks during the first 8 weeks is reasonable. Lower lean-mass reserve also argues for concurrent resistance training and protein intake ≥1.2 g/kg/day to attenuate sarcopenia.

Evidence basis

Published comparative tolerability data for 4-week vs 8-week titration are limited, but real-world practice patterns and the analogous semaglutide literature support equivalent ultimate efficacy with reduced discontinuation rates on slower schedules.

Long-term continuation

SURMOUNT-1 three-year extension (n=1,032 obesity + prediabetes): −19.7% weight at 176 weeks on 15 mg maintenance, with HR 0.07 for progression to T2DM. Continuous chronic therapy is the evidence-supported pathway. Counsel patients to plan for indefinite maintenance or a structured monitored taper.

Maintenance dose selection

Use the lowest dose that maintains the desired weight loss and metabolic targets. Many patients can de-escalate from 15 mg → 10 mg → 7.5 mg once at goal weight. Some find 5 mg adequate as maintenance. Re-escalate if regain occurs.

Withdrawal expectation

SURMOUNT-4: discontinuation of tirzepatide after open-label loss produced significant regain in the placebo-randomized arm, while continued tirzepatide maintained and augmented loss. Expect ~50% of weight lost to return within 12 months of full discontinuation absent intensive lifestyle compensation.

Structured taper

When discontinuation is required (cost, pregnancy planning, patient preference), a step-down over 3–6 months (each step held 4–8 weeks) reduces rebound hunger and regain velocity compared with abrupt stop. Pair taper with intensified behavioral support, structured exercise, and ongoing dietitian engagement.

Pregnancy planning

Discontinue tirzepatide at least 2 months prior to planned conception (allowing ≥4 half-lives plus margin). Tirzepatide is not recommended in pregnancy or lactation. Effective non-oral-hormonal contraception is advised during use; tirzepatide may alter oral contraceptive absorption via gastric emptying delay during initial titration.

Perioperative management

Current anesthesia society guidance (ASA 2023 update) suggests holding tirzepatide for ≥1 week prior to elective procedures requiring general anesthesia or deep sedation due to delayed gastric emptying and aspiration risk. Pulmonary aspiration cases have been reported. Resume after recovery of GI function.

Long-term safety surveillance

SURPASS-CVOT (median 4-year follow-up) and the SURMOUNT-1 three-year extension provide the longest controlled-exposure datasets. Beyond these, post-marketing surveillance is the primary tool. The MTC/MEN-2 boxed warning is a class effect from rodent studies; the human medullary thyroid signal has not materialized in pharmacovigilance to date.

Global dose bands · FDA label + PK bridge

Four fixed dose tiers & weight-band reference.

Tirzepatide is dosed at fixed weekly milligram tiers, not by body weight. The engine anchors every protocol to the label's discrete steps. Per-kg figures are shown only for research/comparison context — the population PK model (19 pooled studies) confirmed body-weight-based adjustment is unnecessary, since PK variability is not clinically meaningful enough to require individualized weight-based dosing. Half-life ≈ 5 days drives once-weekly dosing with steady state by ~4 weeks per step.

Band	Weekly dose (SC)	≈ mg/kg/week (70–80 kg)	Primary basis	Grade
Initiation	2.5 mg/week	~0.03–0.05	Tolerance establishment only — not therapeutic alone; label initiation step.	A
Low / min maintenance	5 mg/week	~0.06–0.09	SURMOUNT-1: −15% body weight at 72 wk; SURPASS-1: HbA1c −1.87%.	A
Standard maintenance	10 mg/week	~0.12–0.18	SURMOUNT-1: −19.5% BW; SURPASS pooled: HbA1c −1.89 to −2.40%.	A
High / maximum	15 mg/week	~0.17–0.27	SURMOUNT-1: up to −20.9% BW; SURPASS: HbA1c up to −2.58%. Label ceiling.	A

7.5 mg and 12.5 mg are also commercial pen strengths used primarily as transition steps, though either can serve as maintenance if tolerated and efficacious. Doses above 15 mg/week are not labeled and carry Grade D.

Weight-band reference (per-kg context only — fixed dosing applies)

Body weight	5 mg/week	10 mg/week	15 mg/week
55 kg (120 lb)	0.091 mg/kg	0.182 mg/kg	0.273 mg/kg
65 kg (143 lb)	0.077 mg/kg	0.154 mg/kg	0.231 mg/kg
75 kg (165 lb)	0.067 mg/kg	0.133 mg/kg	0.200 mg/kg
85 kg (187 lb)	0.059 mg/kg	0.118 mg/kg	0.176 mg/kg
95 kg (209 lb)	0.053 mg/kg	0.105 mg/kg	0.158 mg/kg
105 kg (231 lb)	0.048 mg/kg	0.095 mg/kg	0.143 mg/kg
120 kg (265 lb)	0.042 mg/kg	0.083 mg/kg	0.125 mg/kg

The label does not mandate weight-based dosing; doses are fixed at 2.5/5/7.5/10/12.5/15 mg regardless of body weight. Per-kg values are for research comparison only. No dose adjustment is required for any degree of renal or hepatic impairment. Pediatric safety/efficacy is not established.

Titration logic · engine-ready decision rules

Escalation, hold & stop logic.

These rules are drawn directly from FDA prescribing information and pivotal-trial protocols (Grade A) — unlike most Atlas entries, the escalation cadence, hold logic, and hard stops here are label-validated, not borrowed. Escalation is gated on completing the minimum interval at the current step and adequate tolerability. Hard stops reflect the boxed warning and absolute contraindications.

Decision node	Rule	Rationale	Grade
Escalate	After `≥4 weeks` at current dose AND tolerating well → step by `+2.5 mg` toward target.	Standard label titration schedule; allows steady state before reassessment.	A
Hold	Intolerable GI effects (nausea, vomiting, diarrhea) at current dose → hold current tier an additional `4 weeks` before escalating; slower titration carries no efficacy penalty.	GI events peak during escalation and usually resolve with time-at-dose.	A
De-escalate	Persistent GI intolerance at 10 or 15 mg → reduce to last tolerated dose as new maintenance.	Lower maintenance dose is acceptable per label.	A
Hold (combination)	Initiating with insulin → reduce basal insulin ~20%; with sulfonylurea → reduce 50% or discontinue. Monitor glucose/CGM during titration.	Glucose-dependent secretion means monotherapy rarely causes hypoglycemia, but secretagogue/insulin combinations markedly elevate risk.	A
Hold (perioperative)	Hold ≥1 week before elective procedures requiring general anesthesia/deep sedation (delayed gastric emptying → aspiration risk); resume after GI recovery.	ASA 2023 guidance; pulmonary aspiration cases reported.	B
Permanent stop (hard)	Suspected pancreatitis (severe epigastric pain + lipase elevation) → discontinue, do not restart. Acute gallbladder disease → hold/evaluate.	Class-effect signals; causality uncertain but caution warranted.	A
Permanent stop (hard)	Personal/family history of MTC or MEN2 → contraindicated; do not initiate or restart. Pregnancy identified → discontinue.	Boxed warning (thyroid C-cell tumors, rodent); teratogenicity not excluded.	A

Special populations: no dose adjustment for renal or hepatic impairment. In adults >75 years, GI-driven dehydration can precipitate acute kidney injury — favor conservative (8-week) titration with weight/orthostatic checks during the first 8 weeks. Discontinue ≥2 months before planned conception.

Biomarker scaffold · validated for tirzepatide

Response & safety monitoring bundles.

Unlike research peptides, tirzepatide has trial-defined, biomarker-based endpoints. Most bundles below are validated_for_tirzepatide = true — drawn from SURPASS/SURMOUNT primary endpoints. A minority (routine lipase, calcitonin, C-peptide) are flagged not validated as routine screening and should be checked only on clinical indication.

Biomarker	Frequency	Threshold / action	Validated?
HbA1c (glycemic)	Baseline; q3 mo until stable; q6 mo at goal	Target <7% (T2DM); watch hypoglycemia if on insulin/secretagogue	Yes
Body weight (efficacy)	Baseline; monthly during titration; q3 mo maintenance	≥5% loss at 12 wk = responder threshold	Yes
Fasting plasma glucose	Baseline; monthly during escalation	<130 mg/dL general goal	Yes
Lipid panel (LDL/TG/HDL)	Baseline; q6 mo	TG >500 mg/dL: hold/adjust; expect ↓TG, ↓LDL on therapy	Yes
Systolic BP	Every visit	Mean −6.3 to −6.5 mmHg in trials; target <130 mmHg	Yes
eGFR / creatinine	Baseline; annually	No dose adjustment needed; alert on rapid decline	Yes
AHI (OSA indication)	Baseline sleep study; 12-mo repeat	Target AHI <15 events/hr; do not stop PAP without specialist + repeat PSG	Yes
Amylase / lipase	If symptomatic only — not routine	3× ULN + symptoms → HARD STOP	Not routine
Thyroid calcitonin	Not routine; any neck mass → referral	Not a reliable screening biomarker (FAERS signal exists; routine screening not required)	Not validated
Insulin / C-peptide	Research protocols only	β-cell function research marker; not routine clinical monitoring	Not validated

Architecture note: store each biomarker with a source_endpoint tag and a validated_for_tirzepatide boolean. For tirzepatide most are true (trial-validated) — the inverse of the research-peptide default — which is what distinguishes an approved-drug page from a speculative one.

Standard label titration

Visual titration: from start to maintenance.

Wk 1–4 2.5 mgInitiation Starter · tolerability · not therapeutic

Wk 5–8 5 mgStep 2 First labeled maintenance option

Wk 9–12 7.5 mgStep 3 Transition dose

Wk 13–16 10 mgStep 4 Maintenance option · majority effect

Wk 17–20 12.5 mgStep 5 Transition to top dose

Wk 21+ 15 mgMaximum Maximum maintenance · −20.9% wt

L2 · Dose math

Dose Selection & Reconstitution Calculator

For reference only. Not medical dosing advice. The FDA-approved Lilly product (Mounjaro / Zepbound) is supplied as a single-dose prefilled pen at a fixed concentration — no reconstitution. The default Pen mode reflects this. A secondary Vial mode covers historic multi-dose-vial math for completeness; use the labeled pen wherever possible — FDA has warned against compounded products following shortage resolution.

Calculator mode

Target weekly dose (mg)

Vial size (mg)

BAC water (mL)

Syringe

Concentration

—

Volume to administer
—

Units (U-100 ref)

—

Doses per pen

—

Cadence basis

—

Pen mode mirrors the §3g build note: each strength is a fixed concentration delivering 0.5 mL per single-use dose (2.5 mg→5 mg/mL · 5 mg→10 mg/mL · 7.5 mg→15 mg/mL · 10 mg→20 mg/mL · 12.5 mg→25 mg/mL · 15 mg→30 mg/mL). No BAC water field applies. The calculator functions as a dose-selection guide for the pen and a reconstitution tool only in vial mode.

04 · Combination protocols

Stacking tirzepatide.

Tirzepatide combinations with metformin, SGLT2 inhibitors, and statins are well-evidenced and routinely used. Combinations with other GLP-1 RAs, retatrutide, or compounded incretins are not appropriate. Stacking with weight-loss adjuncts (caffeine, bupropion-naltrexone, phentermine) is variably evidenced. Below: the evidence-based, the mechanistically defensible, and the avoid list.

Tirzepatide Metformin SGLT2 inhibitor Statin

The most evidence-based combination for T2DM with CV/renal risk. Metformin reduces hepatic glucose output (AMPK pathway); SGLT2i provides independent CV and renal benefit (heart failure hospitalization reduction, eGFR slope preservation); tirzepatide adds incretin-mediated insulin and weight effects; statin addresses LDL-driven ASCVD risk. No dose-reductions required at initiation; this combination is the de facto standard of care for T2DM with established CVD or high ASCVD risk.

Component	Mechanism	Evidence
Tirzepatide	GIP/GLP-1 · weight + glycemia + CV	SURPASS-CVOT (A)
Metformin	AMPK · hepatic glucose ↓	1L T2DM (A)
SGLT2 inhibitor	SGLT2 · natriuresis · CV/renal	EMPA-REG / DAPA-HF (A)
Statin	HMG-CoA reductase · LDL ↓	Meta-analyses (A)

Tirzepatide SGLT2 inhibitor MRA (spironolactone/finerenone) Loop diuretic PRN

SUMMIT established tirzepatide as the first medicine with RCT evidence in obesity-related HFpEF — 38% reduction in CV death/worsening HF events, KCCQ-CSS +6.9 points. SGLT2 inhibitors (empagliflozin, dapagliflozin) have parallel HFpEF evidence from EMPEROR-Preserved and DELIVER. The combination targets distinct mechanisms (weight/inflammation/filling pressures via tirzepatide; natriuresis/myocardial energetics via SGLT2i) and is mechanistically rational. MRAs (finerenone preferred in CKD) add fibrosis modification. Diuretics for congestion as needed.

Component	Target	Status
Tirzepatide	Weight · adiposity · BP	SUMMIT (A)
SGLT2i	Natriuresis · cardiac energetics	EMPEROR-Preserved (A)
Finerenone	MR · fibrosis · CKD	FIDELIO/FIGARO (A)
Loop diuretic	Volume management	Symptomatic (A)

Tirzepatide Resmetirom (Rezdiffra) Vitamin E (non-diabetic) SGLT2i

SYNERGY-NASH: 73.3% MASH resolution at 15 mg vs 13.2% placebo, with up to 59% achieving ≥1-stage fibrosis improvement at 52 weeks. Resmetirom (FDA-approved March 2024) is a selective thyroid hormone receptor-β agonist with phase-3 evidence in F2-F3 MASH; combination with tirzepatide is mechanistically distinct (hepatic lipid catabolism via THR-β) and being investigated. Vitamin E 800 IU/day in non-diabetic MASH is supported by PIVENS in some practice patterns. SGLT2i adds independent hepatic fat reductions.

Component	Mechanism	Evidence
Tirzepatide	Weight · adipose · insulin sens	SYNERGY-NASH (B)
Resmetirom	THR-β · hepatic lipid catabolism	MAESTRO-NASH (A)
Vitamin E	Antioxidant · NASH-specific	PIVENS (B)
SGLT2i	Hepatic fat reduction	Meta-analyses (B)

Tirzepatide Resistance training 2–3×/wk Protein 1.2–1.6 g/kg/day Creatine 3–5 g/day Vitamin D 1,000–2,000 IU

~25% of tirzepatide-induced weight loss is lean mass — non-trivial, particularly in older adults and patients with baseline low muscle mass. Resistance training plus adequate protein attenuates this loss. Creatine is the best-evidenced ergogenic supplement and has additive benefit on lean mass and strength. Vitamin D sufficiency supports muscle and bone metabolism. This is the recommended adjunct stack for any patient on chronic tirzepatide therapy — not a separate intervention.

Component	Mechanism	Evidence
Tirzepatide	Weight loss · primary therapy	SURMOUNT (A)
Resistance training	Mechanotransduction · mTORC1	Meta-analyses (A)
Protein 1.2–1.6 g/kg	Substrate for MPS	Consensus (A)
Creatine	Phosphocreatine reserve	Decades RCT (A)

Tirzepatide High-intensity statin SGLT2i Antiplatelet ACE-I/ARB

SURPASS-CVOT showed tirzepatide preserves the cardioprotective signal of dulaglutide with a directionally lower MACE-3 rate (−8%), a significantly lower all-cause mortality (−16%), and improved BP, lipids, and renal function. Standard cardiometabolic protective medications (statin, antiplatelet, RAS blocker, SGLT2i) layer cleanly on top. Each medication targets a distinct mechanism in the cardiometabolic-renal cascade. This is the contemporary standard-of-care stack for T2DM with established ASCVD.

Other GLP-1 RAs (semaglutide, liraglutide, dulaglutide) Retatrutide DPP-4 inhibitors Pramlintide Compounded incretins

Combining tirzepatide with another GLP-1 RA, with retatrutide (triagonist), or with pramlintide produces overlapping mechanisms with no incremental benefit and substantially increased GI and hypoglycemia risk. DPP-4 inhibitors are redundant on a tirzepatide background and should be discontinued. Compounded tirzepatide products should not be used following resolution of the FDA shortage list; quality, purity, and identity vary, and FDA has issued repeated safety alerts. Combining tirzepatide with active sulfonylurea or unmonitored insulin therapy without dose reduction risks severe hypoglycemia.

Scenario	Action	Rationale
Another GLP-1 RA	Discontinue the other agent	Mechanistic redundancy
DPP-4 inhibitor	Discontinue	Redundant on incretin therapy
Sulfonylurea	Reduce 50% or discontinue	Severe hypoglycemia risk
Insulin	Reduce basal 20% + CGM	Severe hypoglycemia risk
Compounded product	Switch to approved Lilly pen	FDA safety warnings
Pregnancy planning	Discontinue ≥2 months prior	No human pregnancy data

Tirzepatide vs. the incretin family

Agent	Receptor profile	Approved indications	Dosing	Weight loss	Status
Tirzepatide	GIP + GLP-1 (dual)	T2DM · obesity · OSA	Weekly SC · 2.5 → 15 mg	−20.9% (SURMOUNT-1, 15 mg, 72 wk)	FDA-approved (A)
Semaglutide (Ozempic / Wegovy)	GLP-1 (selective)	T2DM · obesity · CV risk reduction	Weekly SC · 0.25 → 2.4 mg	−13.7% (SURMOUNT-5, 2.4 mg, 72 wk)	FDA-approved (A)
Dulaglutide (Trulicity)	GLP-1 (selective)	T2DM · CV risk reduction	Weekly SC · 0.75 → 4.5 mg	~3–5% modest	FDA-approved (A)
Liraglutide (Saxenda / Victoza)	GLP-1 (selective)	T2DM · obesity · pediatric obesity	Daily SC · 0.6 → 3.0 mg	~5–8%	FDA-approved (A)
Retatrutide (LY3437943)	GIP + GLP-1 + glucagon (triple)	None (phase 3)	Weekly SC · up to 12 mg	−24.2% at 48 wk (phase 2, 12 mg)	Investigational (A pre-3)
Oral semaglutide (Rybelsus)	GLP-1 (selective, oral)	T2DM	Daily oral · 3 → 14 mg	~3–4%	FDA-approved (A)
Survodutide (BI 456906)	GLP-1 + glucagon (dual)	None (phase 3)	Weekly SC	~14% (phase 2, MASH)	Investigational (B)
Orforglipron (LY3502970)	GLP-1 (selective, non-peptide oral)	None (phase 3)	Daily oral	~14.7% at 36 wk (phase 2)	Investigational (B)

05 · Safety profile & contraindications

Well-characterized class; known boxed warning.

Tirzepatide's safety profile is established through >13,000 patient-years in the SURPASS, SURMOUNT, SUMMIT, SYNERGY-NASH, and SURPASS-CVOT programs, plus post-marketing surveillance since 2022. The dominant adverse-event burden is gastrointestinal during titration. The class boxed warning for medullary thyroid carcinoma (MTC) reflects rodent C-cell tumor findings; the human signal has not materialized. Hypoglycemia is largely a function of background medications. Pancreatitis, gallbladder disease, and renal injury from dehydration are known low-incidence risks.

Common Adverse Events (SURPASS / SURMOUNT pooled)

Nausea~22–33% across pivotal trials; dose-dependent and titration-related. Mild-to-moderate in most cases. Peaks 1–2 weeks after each escalation step; resolves with dose stabilization or step-back.

Diarrhea~17–22% — most common in T2DM populations with concurrent metformin. Generally mild; persistent severe diarrhea warrants dose hold and evaluation for alternative etiologies.

Vomiting~9–13% — dose-dependent. Severe vomiting risks dehydration and acute kidney injury, particularly in elderly. Hold dose, hydrate, ondansetron PRN, reassess at next scheduled step.

Constipation~6–11% — secondary to slowed gastric emptying and reduced food/fiber intake. Increase fiber, fluids, gentle laxative (PEG 3350) PRN.

Decreased appetite~7–10% reported as AE, though it is also the desired effect. Becomes problematic when paired with markedly reduced caloric intake that risks protein deficit.

Injection-site reactions~3–5% — mild erythema, pruritus, transient pain. Rotate sites; warm the pen 30 min before injection.

Fatigue~5–7% — particularly during early titration as metabolism shifts. Generally self-resolves.

Discontinuation due to AEsSURPASS-CVOT: 13.3% on tirzepatide vs 10.2% on dulaglutide. SURMOUNT-1: ~6% on tirzepatide vs ~3% on placebo. Discontinuation is dose-related and higher at 15 mg than 5–10 mg.

Boxed Warning & Serious Adverse Events

BOXED · Medullary thyroid carcinoma (MTC)Class boxed warning. Rodent C-cell tumors observed in carcinogenicity studies. Human signal has not materialized in pharmacovigilance. Contraindicated in personal/family history of MTC or MEN-2.

PancreatitisAcute pancreatitis reported as low-incidence class effect. Caution in history of pancreatitis (not formally studied in this population). Discontinue if pancreatitis suspected (severe abdominal pain, elevated lipase); do not restart if confirmed.

Severe hypoglycemiaRare in monotherapy or with metformin/SGLT2i alone. Significantly elevated with concurrent insulin or sulfonylurea — proactive dose reduction of those agents at tirzepatide initiation is required.

Acute kidney injuryFrom volume depletion in patients with severe GI symptoms (vomiting, diarrhea). Higher risk in elderly, baseline CKD, RAAS blockade, or diuretic use. Hydration counseling; hold dose if severe.

Gallbladder diseaseCholelithiasis and cholecystitis reported as class effect, linked to rapid weight loss. Counsel on RUQ pain; imaging if symptomatic.

HypersensitivityAnaphylaxis and angioedema rarely reported. Contraindicated in known hypersensitivity to tirzepatide or excipients.

Diabetic retinopathy progressionTheoretical risk from rapid glycemic improvement in patients with pre-existing retinopathy. Baseline eye exam in T2DM patients with known retinopathy; closer follow-up during titration.

Pulmonary aspiration · anesthesiaReports of aspiration under general anesthesia due to delayed gastric emptying. Hold tirzepatide ≥1 week prior to elective procedures requiring general anesthesia or deep sedation (ASA 2023 guidance).

Suicidal ideation signalFDA evaluated post-marketing reports across GLP-1 class (2024); no causal association established. Continue routine mental-health screening; report new symptoms.

Contraindication reference

Condition / factor	Risk level	Applies to	Rationale
Personal/family history of medullary thyroid carcinoma (MTC)	Contraindicated	All	Boxed warning · rodent C-cell tumor signal · MTC/MEN-2 are absolute contraindications per FDA label.
Multiple Endocrine Neoplasia syndrome type 2 (MEN-2)	Contraindicated	All	Boxed warning · genetic predisposition to MTC.
Pregnancy	Avoid	All	No human pregnancy data · animal studies show embryofetal toxicity. Discontinue ≥2 months prior to planned conception.
Lactation	Avoid	All	Excretion into breast milk unknown · insufficient data · avoid until lactation complete.
Pediatric (< 18 years)	Avoid	All	Not labeled for use in pediatrics. Pediatric trials underway. Liraglutide is the only incretin currently approved for pediatric obesity.
Hypersensitivity to tirzepatide	Contraindicated	All	Anaphylaxis and angioedema reported · contraindication per label.
Prior pancreatitis	Caution	All	Not formally studied in this population · specialist input · weigh against alternative therapies.
Concurrent insulin therapy	Monitor	T2DM	Reduce basal insulin 20% at initiation · CGM during titration · hypoglycemia risk significantly elevated without adjustment.
Concurrent sulfonylurea	Monitor	T2DM	Reduce SU dose 50% or discontinue · severe hypoglycemia risk.
Severe gastroparesis / motility disorder	Caution	All	Tirzepatide further delays gastric emptying · symptoms may worsen · weigh against alternatives.
Active gallbladder disease	Caution	All	Class effect with rapid weight loss · symptomatic stones may worsen.
Pre-existing severe diabetic retinopathy	Monitor	T2DM	Theoretical risk from rapid glycemic improvement · baseline retinal exam · closer follow-up during titration.
Severe renal impairment (eGFR < 30)	Monitor	All	No formal dose adjustment required by label, but volume depletion from GI AEs disproportionately raises AKI risk in CKD · monitor renal function · counsel hydration.
Elective surgery requiring anesthesia	Caution	All	Hold tirzepatide ≥1 week pre-procedure per ASA 2023 guidance · pulmonary aspiration risk from delayed gastric emptying.
Severe psychiatric instability · active SI	Monitor	All	No causal association established · continue routine MH screening · report new symptoms.
Compounded product from unverified source	Avoid	All	FDA has issued multiple safety warnings · purity, identity, and dosing accuracy vary · use approved Lilly pen.
Concurrent oral contraceptive (initial 4 wk)	Monitor	Reproductive age	Delayed gastric emptying may reduce OCP absorption during initial titration · use barrier backup or non-oral contraception for first 4 weeks.

Suggested monitoring for tirzepatide protocols

Baseline

HbA1c, fasting glucose, lipid panel, CMP (LFTs, renal), TSH, eGFR (CKD-EPI-Cr-CysC 2021 in obesity), BMI, waist circumference, BP, HR. Pregnancy test if reproductive potential. Personal/family thyroid cancer history screen. Baseline retinal exam in T2DM with known retinopathy. Body composition (DEXA) optional in obesity protocol.

4-Week Step Checks

Symptom review (GI tolerability, hydration, weight trend). Decision: escalate, hold, or step back. In T2DM with insulin/SU: SMBG or CGM data review for hypoglycemia. In obesity: weight trend confirms response or triggers reassessment.

12-Week / End-of-Titration

Repeat A1c (T2DM), weight, BP, waist circumference. Reassess maintenance dose target. In OSA indication: clinical sleep symptom review; consider follow-up sleep study at 6–12 months if PAP weaning being considered.

6 Months

Full repeat baseline panel: A1c, lipids, CMP, eGFR, BP, weight, waist. Reassess medication titration (insulin, SU, antihypertensives). Confirm response thresholds — ≥5% weight loss expected by 6 months. Re-counsel on chronic-therapy framing.

Annual

Full metabolic panel · body composition (DEXA) if available · BMD if >65 years and chronic therapy >2 years (osteopenia screen given lean mass loss). Reassess indication, ongoing benefit, and continued tolerability. Document new diagnoses (cancer, pregnancy planning) that change risk/benefit.

Stop / Hold Criteria

Suspected acute pancreatitis (severe abdominal pain + elevated lipase) → permanent discontinuation if confirmed. New MTC or MEN-2 diagnosis → discontinue. Planned pregnancy → discontinue ≥2 months prior. Elective surgery requiring anesthesia → hold ≥1 week. Severe AKI from GI volume depletion → hold and rehydrate; resume cautiously after recovery. New severe psychiatric symptoms → individual risk/benefit reassessment.

06 · Key studies & research program

The SURPASS, SURMOUNT, SUMMIT, and SURPASS-CVOT program.

Tirzepatide's evidence base is among the largest in pharmaceutical history — six SURPASS T2DM trials, five SURMOUNT obesity trials, a 13,000-patient cardiovascular outcomes trial, an HFpEF outcomes trial, a phase-2 MASH trial, a sleep-apnea trial program, and an ongoing morbidity/mortality obesity CVOT. Below: the trials that define the clinical positioning of the molecule, organized by indication and chronology.

SURMOUNT-1 · obesity

−20.9%

Weight loss at 72 weeks · 15 mg · n=2,539 · NEJM 2022 · the pivotal obesity readout

SURPASS-2 · T2DM

−2.46%

HbA1c at 40 wk · 15 mg vs sema 1 mg (−1.86%) · NEJM 2021 · head-to-head superiority

SURMOUNT-5 · vs sema

−20.2 vs −13.7

% weight at 72 wk · tirz 10/15 vs sema 1.7/2.4 mg · NEJM 2025 · definitive head-to-head

SURPASS-CVOT

−16% ACM

All-cause mortality vs dulaglutide · n=13,299 · NEJM 393:2409–2420 · Dec 2025

A Phase 3 · obesity · anchor readout

SURMOUNT-1 — Jastreboff et al. 2022 (NEJM)

Adults with BMI ≥30 (or ≥27 + comorbidity) without diabetes, randomized to tirzepatide 5/10/15 mg vs placebo for 72 weeks; n=2,539. Mean weight change (efficacy estimand) at 72 weeks: −15.0% (5 mg), −19.5% (10 mg), −20.9% (15 mg) vs −3.1% placebo; all P<0.001. ≥5% loss achieved in ≥85% of all active arms; ≥20% loss in ~56% (15 mg). The pivotal obesity readout that supported November 2023 FDA approval.

PMID 35658024 NCT04184622

A Phase 3 extension · 176 weeks · prediabetes

SURMOUNT-1 Three-Year Extension — 2025 (NEJM)

Among the SURMOUNT-1 participants with obesity and prediabetes (n=1,032), the trial continued to 176 weeks. Mean weight change at 176 weeks: −12.3% (5 mg), −18.7% (10 mg), −19.7% (15 mg) vs −1.3% placebo. Progression to T2DM: 1.3% with tirzepatide vs 13.3% with placebo (HR 0.07; 95% CI 0.02–0.24). Off-treatment 17-week follow-up: T2DM 2.4% vs 13.7% (HR 0.12; 95% CI 0.05–0.28) — partial durability after discontinuation.

PMID 39536238

A Phase 3 · obesity + T2DM

SURMOUNT-2 — Garvey et al. 2023 (Lancet)

Adults with BMI ≥27 and T2DM randomized to tirzepatide 10 or 15 mg vs placebo for 72 weeks. Mean weight loss ≈15% (≈14.8 kg) in active arms vs ~3% placebo; baseline A1c ~8.0% → ~5.9%. ≥5% loss in 79–83% of tirzepatide arms vs 32% placebo. Demonstrated that obesity-level weight loss is achievable in T2DM populations, who historically show blunted responses to weight-loss pharmacotherapy.

PMID 37385275 NCT04657003

A Phase 3 · obesity · post-lifestyle

SURMOUNT-3 — Wadden et al. 2023 (Nature Medicine)

Adults with obesity (or overweight + comorbidity) who completed a 12-week intensive lifestyle run-in achieving ≥5% loss were randomized to tirzepatide vs placebo for 72 weeks. Tirzepatide produced substantial additional double-digit weight reduction beyond the lifestyle baseline, while placebo arm regained. Health-related quality of life improved significantly in tirzepatide arm. Operationalized pharmacotherapy as a continuation strategy after lifestyle-induced loss.

PMID 37840095 NCT04657016

A Phase 3 · withdrawal trial

SURMOUNT-4 — Aronne et al. 2023 (JAMA)

Participants received open-label tirzepatide for 36 weeks (achieving substantial weight loss), then were randomized to continue tirzepatide or switch to placebo for 52 weeks. Withdrawal produced substantial weight regain over the placebo follow-up period; continuation maintained and augmented initial loss. Established the chronic-therapy framing for tirzepatide and informed counseling on indefinite maintenance vs structured taper.

PMID 38078870

A Phase 3 · head-to-head vs semaglutide

SURMOUNT-5 — Aronne et al. 2025 (NEJM 393:26-36)

The first definitive head-to-head obesity RCT: tirzepatide 10/15 mg vs semaglutide 1.7/2.4 mg over 72 weeks; n=751. LSM weight change −20.2% (tirzepatide) vs −13.7% (semaglutide), P<0.001. Waist circumference −18.4 vs −13.0 cm. Significantly higher proportions on tirzepatide achieved ≥10%, ≥15%, ≥20%, ≥25% loss. Established tirzepatide as the most potent approved obesity medication at the time of publication.

PMID 40353578 NCT05822830

A Phase 3 · T2DM monotherapy

SURPASS-1 — Rosenstock et al. 2021 (Lancet)

Adults with T2DM inadequately controlled on diet/exercise alone randomized to tirzepatide 5/10/15 mg vs placebo for 40 weeks; n=478. HbA1c change: −1.87% (5 mg), −1.89% (10 mg), −2.07% (15 mg) vs +0.04% placebo. Weight change: −7.0 / −7.8 / −9.5 kg vs −0.7 kg. First monotherapy SURPASS readout; demonstrated effect size unprecedented in T2DM monotherapy trials.

PMID 34186022 NCT03954834

A Phase 3 · head-to-head vs semaglutide 1 mg

SURPASS-2 — Frías et al. 2021 (NEJM)

Adults with T2DM on metformin randomized to tirzepatide 5/10/15 mg vs semaglutide 1 mg for 40 weeks; n=1,879. HbA1c reduction: −2.09% (5 mg), −2.37% (10 mg), −2.46% (15 mg) vs −1.86% (sema 1 mg); all tirzepatide doses superior (P<0.001). Weight change: −7.6 / −9.3 / −11.2 kg vs −5.7 kg. Established tirzepatide's superiority over the then-leading injectable GLP-1 RA in T2DM.

PMID 34170647 NCT03987919

A Phase 3 · T2DM vs insulin degludec

SURPASS-3 — Ludvik et al. 2021 (Lancet)

Adults with T2DM on metformin ± SGLT2i randomized to tirzepatide 5/10/15 mg vs titrated insulin degludec for 52 weeks; n=1,444. Tirzepatide superior on A1c and weight: A1c reductions −1.93 to −2.37% vs −1.34% (degludec); weight −7.5 to −12.9 kg vs +2.3 kg. Demonstrated tirzepatide could replace basal insulin initiation in many patients.

PMID 34370970 NCT03882970

A Phase 3 · T2DM + high CV risk

SURPASS-4 — Del Prato et al. 2021 (Lancet)

Adults with T2DM and increased CV risk on metformin/SGLT2i/SU randomized to tirzepatide 5/10/15 mg vs titrated insulin glargine for 52 weeks; n=2,002. A1c reductions −2.11 to −2.58% vs −1.44% (glargine); weight −7.1 to −11.7 kg vs +1.9 kg. Prespecified MACE-4 secondary analysis showed favorable trend (HR 0.74) — informed the design of SURPASS-CVOT.

PMID 34672967 NCT03730662

A Phase 3 · add-on to basal insulin

SURPASS-5 — Dahl et al. 2022 (JAMA)

Adults with T2DM inadequately controlled on insulin glargine ± metformin randomized to tirzepatide 5/10/15 mg vs placebo for 40 weeks; n=475. A1c reductions: −2.11% (5 mg), −2.40% (10 mg), −2.34% (15 mg) vs −0.86% placebo. Weight: −5.4 / −8.8 / −10.5 kg vs +1.6 kg. Established tirzepatide as effective add-on to basal insulin and provided framework for combined-therapy dosing.

PMID 35133415 NCT04039503

A Phase 3 · cardiovascular outcomes

SURPASS-CVOT — Nicholls et al. 2025 (NEJM 393:2409–2420)

Event-driven CVOT comparing tirzepatide vs dulaglutide in adults with T2DM and established ASCVD; n=13,299; median follow-up 4 years. Tirzepatide non-inferior on MACE-3 with numerically 8% lower rate; significantly 16% lower all-cause mortality; superior on A1c, weight, BP, lipids, and renal function (eGFR by CKD-EPI-Cr-CysC). Broader MACE-4 (incl. coronary revascularization): 16.5% vs 18.5%, favoring tirzepatide. Discontinuation due to AEs: 13.3% vs 10.2%. Definitive CV evidence; supports CV risk-reduction labeling consideration.

NEJM 393:2409 NCT04255433

A Phase 3 · HFpEF outcomes

SUMMIT — Packer et al. 2024 (NEJM)

Adults with NYHA II–IV HFpEF (LVEF ≥50%) and BMI ≥30 randomized to tirzepatide vs placebo; n=731; follow-up to 104 weeks. Composite of CV death or worsening HF events reduced ~38% relative to placebo. KCCQ-CSS improved by +6.9 points vs placebo at 52 weeks; 6MWD improved ~+18 m; weight loss ~11–12% greater than placebo. First medicine with prospective RCT evidence in HFpEF mediated principally through weight reduction.

NEJM 2024 NCT04847557

A Phase 3 · OSA + obesity

SURMOUNT-OSA — Malhotra et al. 2024 (NEJM)

Master-protocol phase 3: adults with moderate-to-severe OSA (AHI ≥15) and obesity (BMI ≥30), with (Study 2, n=235) or without (Study 1, n=234) PAP therapy, randomized to tirzepatide 10/15 mg vs placebo for 52 weeks. AHI reduction from baseline: Study 1 −27.4 vs −4.8 events/h; Study 2 −29.3 vs −5.5 events/h. ~50% of treated patients achieved AHI reductions large enough to no longer meet OSA criteria. Hypoxic burden and hs-CRP also significantly reduced. Supported FDA approval December 20, 2024 — the first medicine indicated for OSA.

NEJM 2024 NCT05412004

B Phase 2 · MASH

SYNERGY-NASH — Loomba et al. 2024 (NEJM 391:299–310)

Phase 2 RCT in adults with biopsy-proven MASH and F2-F3 fibrosis randomized to tirzepatide 5/10/15 mg vs placebo for 52 weeks; n=190. MASH resolution without worsening fibrosis (efficacy estimand): 51.8% (5 mg), 62.8% (10 mg), 73.3% (15 mg) vs 13.2% placebo. ≥1-stage fibrosis improvement without MASH worsening: 59.1% / 53.3% / 54.2% vs 32.8% placebo. Safety consistent with prior SURPASS/SURMOUNT. Phase 3 ongoing.

NEJM 2024 NCT04166773

D Phase 3 · ongoing · CVOT in obesity (no T2DM)

SURMOUNT-MMO — Lam et al. 2025 (rationale; Obesity 33:1645)

Ongoing pivotal placebo-controlled CV-outcomes trial in obesity without T2DM. 5-point composite primary endpoint (all-cause death, non-fatal MI, non-fatal stroke, coronary revascularization, heart failure events). Secondary endpoints include T2DM incidence, eGFR change, and physical functioning. The placebo-controlled obesity CVOT for tirzepatide; results expected 2026+. Continues past 3 years of follow-up at time of writing.

Rationale paper NCT05556512

B Mechanistic · receptor pharmacology

Willard et al. 2020 — "imbalanced and biased" agonism (JCI Insight)

Demonstrated that tirzepatide produces robust cAMP at GIPR with full agonist behavior, while at GLP-1R it shows reduced β-arrestin recruitment relative to native GLP-1 and semaglutide — the "imbalanced and biased" signature. This signaling-bias signature is one proposed mechanism for tirzepatide's greater per-dose efficacy vs equipotent selective GLP-1 RAs. The reference mechanistic paper for understanding tirzepatide's pharmacology at the two receptors.

PMID 32730231

A Pooled analysis · normoglycemia

Pooled SURPASS-1 to -5 normoglycemia analysis — Heise et al. 2023 (Diabetes Care)

Patient-level pooled analysis across SURPASS-1 through SURPASS-5. 23–62% of tirzepatide-treated participants achieved HbA1c <5.7% (normoglycemia) depending on trial and dose, without increased hypoglycemia risk vs placebo. Normoglycemia probability scales with dose, lower baseline A1c, shorter T2DM duration, and absence of background insulin. Highest documented normoglycemia rate in any T2DM pharmacotherapy program.

PubMed

D Regulatory · OSA indication

FDA approval — Zepbound for OSA (December 20, 2024)

FDA approved Zepbound (tirzepatide) for moderate-to-severe OSA in adults with obesity on December 20, 2024 — the first prescription medicine indicated for sleep apnea. Approval based on the SURMOUNT-OSA master-protocol phase 3 program (Study 1 non-PAP, Study 2 on-PAP). Adjunct to reduced-calorie diet and increased physical activity; not a PAP replacement in isolation.

FDA / Lilly

D Pipeline · next-generation

Pipeline — oral tirzepatide & long-acting formulations

Eli Lilly is developing an oral tirzepatide formulation and exploring once-monthly (or longer-acting) dosing schedules. As of May 2026, both remain pre-pivotal. Orforglipron (non-peptide oral GLP-1 RA) and retatrutide (triagonist) are the other Lilly incretin-pipeline molecules with relevant adjacencies. Tirzepatide remains the most advanced dual-incretin approved agent globally.

Lilly pipeline

Read-out signal

Tirzepatide is the most fully characterized peptide in the Atlas. Within four years of first approval (May 2022), it has read out the largest obesity RCT ever conducted, the first dual-incretin CVOT, the first medicine in HFpEF mediated by weight, the first medicine indicated for OSA, and the first phase-3-ready dataset in MASH — across three approved indications. The remaining open questions are: (1) magnitude of CV benefit in obesity without diabetes (SURMOUNT-MMO); (2) dedicated CKD outcome data; (3) phase-3 MASH; (4) pediatric labeling. Tirzepatide is the current standard-of-care benchmark against which retatrutide, oral incretins, and next-generation agents will be measured.

07 · Compare & contrast

Tirzepatide vs. its siblings.

A feature-by-feature comparison against the agents tirzepatide is most often measured against: its closest selective-GLP-1 sibling (semaglutide), the next-generation triagonist that may exceed it (retatrutide), the SURPASS-CVOT comparator (dulaglutide), and the longest-tenured GLP-1 in the class (liraglutide). Where tirzepatide has been compared head-to-head, the result is cited.

Feature	Tirzepatide	Semaglutide	Retatrutide	Liraglutide
Mechanism class	Dual GIP/GLP-1	Selective GLP-1	Triple GIP/GLP-1/glucagon	Selective GLP-1
Primary use	T2DM · obesity (BMI ≥27) · OSA	T2DM · obesity · CVD risk reduction	T2DM · obesity (Phase 3)	T2DM · obesity · CVD · pediatric obesity
Evidence tier	A — multiple large Phase 3 RCTs + CVOT	A — multiple large Phase 3 RCTs	Phase 3 ongoing (~2027 approval est.)	A — approved, longest record
Route / frequency	SC weekly	SC weekly; oral daily (Rybelsus)	SC weekly (investigational)	SC daily (Victoza/Saxenda)
Weight-loss ceiling	−20.9% (15 mg, SURMOUNT-1)	−13.7 to −17.4% (2.4 mg)	~−24% (12 mg, Phase 2)	−6 to −8% (3.0 mg)
Head-to-head vs tirzepatide	—	Beaten: −20.2 vs −13.7% (SURMOUNT-5)	Not yet (different sponsor program)	Not direct; tirz superior class-wide
FDA status	Approved · 3 indications	Approved (Ozempic/Wegovy/Rybelsus)	Investigational	Approved (Victoza/Saxenda)
Half-life	~5 days	~7 days	~6 days (est.)	~13 hours
WADA status	Monitoring program (not prohibited)	Monitoring program (not prohibited)	Not on list	Not on list
Compounding	Restricted (shortage resolved)	Restricted (shortage resolved)	N/A (investigational)	Generic liraglutide available

Sibling profiles

08 · Three reading layers

One molecule, three depths.

Every section of this page rewrites itself for consumer, clinician, or researcher via the depth selector at the top. Below, the same summary is held at all three layers at once — the clearest way to see how the framing shifts with the reader.

L1 · Consumer · plain language

Tirzepatide (brand names Mounjaro and Zepbound) is an FDA-approved weekly injection that helps control blood sugar, drives significant weight loss, and is now also approved for obstructive sleep apnea. It works by mimicking two natural gut hormones — GIP and GLP-1 — that regulate appetite and insulin, which makes it more effective than older treatments that copy only one hormone. It is taken as a once-weekly shot from a prefilled pen, started low and increased slowly to limit nausea.

L2 · Clinical · practitioner framing

Tirzepatide (LY3298176) is a first-in-class dual GIP/GLP-1 receptor co-agonist approved across three indications: T2DM glycemic management (Mounjaro, 2022), chronic weight management at BMI ≥27 with comorbidity (Zepbound, 2023), and moderate-to-severe OSA in adults with obesity (Zepbound, 2024). The dual-receptor mechanism produces synergistic incretin effects — superior HbA1c reduction (up to −2.58%), weight loss (up to −20.9% at 15 mg), and cardiometabolic improvement — versus GLP-1 monotherapy. Once-weekly SC dosing (2.5–15 mg titration ladder) with a ~5-day half-life supports adherence; GI tolerability is the primary limitation, and the MTC/MEN-2 boxed warning is the principal contraindication gate.

L3 · Research · molecular / pathway level

Tirzepatide is a 39-amino-acid acylated synthetic peptide (C₂₂₅H₃₄₈N₄₈O₆₈; MW ≈ 4813 Da) engineered from native GIP with two α-aminoisobutyric acid (Aib) substitutions for DPP-4 resistance, conjugated to a C20 fatty diacid via a γ-Glu/(AEEA)₂ linker at Lys20 for albumin binding and a ~5-day half-life. It achieves balanced co-agonism at GIPR and GLP-1R via Gs/cAMP/PKA signaling across pancreatic β/α cells, hypothalamic arcuate nucleus, adipocytes, and cardiorenal tissue — GIP-arm potency near native GIP, GLP-1R arm below native GLP-1 but synergistically amplified in vivo, with reduced β-arrestin recruitment ("imbalanced and biased"). The imbalanced co-agonism yields metabolic outcomes exceeding single-receptor GLP-1 agonists in head-to-head Phase 3 trials, with a validated population PK model (19 pooled studies, two-compartment, first-order) supporting fixed-dose weekly regimens without weight-based adjustment.

09 · Evidence & references

Every claim, graded and sourced.

A · RCT / meta-analysis

B · Large cohort / consistent trial set

C · Small trial / mechanistic

P · Preclinical / animal

D · Expert / textbook / regulatory

Explore the ATLAS index